NASDAQ:EVAX

Evaxion Biotech A/S Competitors

$6.98
+0.13 (+1.90 %)
(As of 04/20/2021 10:32 AM ET)
Add
Compare
Today's Range
$6.98
Now: $6.98
$6.98
50-Day Range
$5.20
MA: $6.68
$7.80
52-Week Range
$5.16
Now: $6.98
$10.34
Volume100 shs
Average Volume117,262 shs
Market Capitalization$134.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Evaxion Biotech A/S (NASDAQ:EVAX) Vs. IVA, SGTX, GMTX, LABP, TERN, and NEXI

Should you be buying EVAX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Evaxion Biotech A/S, including Inventiva (IVA), Sigilon Therapeutics (SGTX), Gemini Therapeutics (GMTX), Landos Biopharma (LABP), Terns Pharmaceuticals (TERN), and NexImmune (NEXI).

Evaxion Biotech A/S (NASDAQ:EVAX) and Inventiva (NYSE:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Inventiva's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
InventivaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evaxion Biotech A/S and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Inventiva10402.60

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 104.13%. Given Evaxion Biotech A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Inventiva.

Profitability

This table compares Evaxion Biotech A/S and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
InventivaN/AN/AN/A

Summary

Evaxion Biotech A/S beats Inventiva on 2 of the 3 factors compared between the two stocks.

Evaxion Biotech A/S (NASDAQ:EVAX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Sigilon Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evaxion Biotech A/S and Sigilon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Sigilon Therapeutics01302.75

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 251.31%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Evaxion Biotech A/S.

Profitability

This table compares Evaxion Biotech A/S and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

Sigilon Therapeutics beats Evaxion Biotech A/S on 2 of the 3 factors compared between the two stocks.

Evaxion Biotech A/S (NASDAQ:EVAX) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Gemini Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
Gemini TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Evaxion Biotech A/S and Gemini Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
Gemini TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evaxion Biotech A/S and Gemini Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Gemini Therapeutics00403.00

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Gemini Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 96.08%. Given Evaxion Biotech A/S's higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Gemini Therapeutics.

Evaxion Biotech A/S (NASDAQ:EVAX) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Evaxion Biotech A/S and Landos Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
Landos BiopharmaN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Evaxion Biotech A/S and Landos Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Landos Biopharma01302.75

Evaxion Biotech A/S presently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Landos Biopharma has a consensus target price of $25.50, suggesting a potential upside of 142.17%. Given Evaxion Biotech A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Evaxion Biotech A/S is more favorable than Landos Biopharma.

Earnings and Valuation

This table compares Evaxion Biotech A/S and Landos Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
Landos BiopharmaN/AN/AN/AN/AN/A

Summary

Evaxion Biotech A/S beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Terns Pharmaceuticals (NASDAQ:TERN) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Earnings and Valuation

This table compares Terns Pharmaceuticals and Evaxion Biotech A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Profitability

This table compares Terns Pharmaceuticals and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Terns PharmaceuticalsN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Terns Pharmaceuticals and Evaxion Biotech A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Terns Pharmaceuticals00303.00
Evaxion Biotech A/S00203.00

Terns Pharmaceuticals currently has a consensus price target of $30.50, suggesting a potential upside of 82.20%. Evaxion Biotech A/S has a consensus price target of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher possible upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Terns Pharmaceuticals.

NexImmune (NASDAQ:NEXI) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Profitability

This table compares NexImmune and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NexImmuneN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Earnings & Valuation

This table compares NexImmune and Evaxion Biotech A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NexImmuneN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for NexImmune and Evaxion Biotech A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NexImmune00303.00
Evaxion Biotech A/S00203.00

NexImmune presently has a consensus target price of $33.3333, suggesting a potential upside of 81.55%. Evaxion Biotech A/S has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher probable upside, analysts clearly believe Evaxion Biotech A/S is more favorable than NexImmune.


Evaxion Biotech A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inventiva logo
IVA
Inventiva
1.4$13.39+0.4%$517.26 millionN/A0.00News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$15.03+6.9%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.95+2.5%$482.45 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.60+2.4%$435.28 millionN/A0.00Gap Up
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.50+3.6%$429.64 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$18.36+2.1%$417.84 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$13.72+3.8%$403.76 millionN/A0.00Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$12.82+5.9%$400.10 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$29.40+8.2%$355.24 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.80+8.1%$283.89 millionN/A-2.55
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.01+2.7%$262.02 millionN/A-2.38
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.73+1.1%$245.04 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.03+1.1%$240.80 millionN/A0.00Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.14+8.1%$188.90 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$10.00+1.3%$171.37 millionN/A0.00Quiet Period Expiration
Gap Up
GANX
Gain Therapeutics
1.7$12.96+7.8%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.30+3.1%$152.49 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.23+0.0%$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$28.47+21.1%$80.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.52+0.9%$77.21 millionN/A0.00News Coverage
Gap Up
VRDN
Viridian Therapeutics
1.7$15.04+1.9%$58.78 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.19+1.0%$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.59+0.2%$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.40+2.0%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.45+0.3%$38.08 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$2.94+1.0%$34.28 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.39+3.6%$29.90 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.15+2.7%$21.07 millionN/A0.00News Coverage
Gap Up
BCTX
BriaCell Therapeutics
0.0$2.89+8.0%$2.41 millionN/A0.00Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.54+0.8%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00
BMEA
Biomea Fusion
0.0$16.70+1.8%$0.00N/A0.00High Trading Volume
Gap Up
RXRX
Recursion Pharmaceuticals
0.0$29.58+5.3%$0.00N/A0.00High Trading Volume
Gap Up
RPHM
Reneo Pharmaceuticals
0.3$12.75+0.2%$0.00N/A0.00
SCPS
Scopus BioPharma
1.4$7.59+1.4%$0.00N/A0.00
VECT
VectivBio
0.0$15.27+0.1%$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.